d $(0.01) $0.01 $0.01 $0.01
Weighted average shares
outstanding:
Basic 45,292 45,274 45,292 45,274
Diluted 45,292 45,274 45,328 45,274
CARDIOGENESIS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
September December
30, 2008 31, 2007
(unaudited) (audited)
ASSETS
Current assets:
Cash and cash equivalents $3,439 $2,824
Accounts receivable, net of allowance for
doubtful accounts of $49 and $28,
respectively 1,319 1,763
Inventories 1,380 1,602
Prepaids and other current assets 466 486
Total current assets 6,604 6,675
Long-term investments in marketable securities 75 --
Property and equipment, net 341 457
Other assets, net 27 27
Total assets $7,047 $7,159
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $338 $169
Accrued liabilities 1,124 1,458
Deferred revenue 902 1,210
Current portion of capital lease obligation 8 12
Total current liabilities
'/>"/>
SOURCE Cardiogenesis Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results2.
Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th3.
AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results4.
Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results5.
China Biologic Products Reports Strong Third Quarter 2008 Results6.
Imagenetix, Inc. Reports Second Quarter and Six Month Results7.
TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments8.
China-Biotics, Inc. Reports Second Quarter 2009 Financial Results9.
Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units10.
Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year11.
Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results